MedTrace Logo

The Use of Low Molecular Weight Heparin in Traumatic Brain Injury

NCT00170378 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2017-06-27

No results posted yet for this study

Summary

To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.

Conditions

  • Brain Injury
  • Venous Thrombosis

Interventions

DRUG

Enoxaparin

Sponsors & Collaborators

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • Hennepin Healthcare Research Institute

    lead OTHER

Principal Investigators

  • John K. Cumming, M.D. · Hennepin County Medical Center/MinneapolisMRF

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Completion
2005-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00170378 on ClinicalTrials.gov